Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Names Stephen Aselage President and Chief Operations Officer
Seasoned industry executive has strong track record in commercialization of rare disease products NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Stephen Aselage as President and Chief Operations Officer, effective immediately. In his new role, Mr.
View HTML
Toggle Summary Retrophin Reports First Quarter 2014 Financial Results
Management to Host Conference Call and Webcast Today at 8:30 a.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today reported its financial results for the quarter ended March 31, 2014 . "The first quarter of 2014 was a transformative period for Retrophin," said Martin Shkreli ,
View HTML
Toggle Summary Retrophin to Report First Quarter 2014 Financial Results
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) announced today that it will report its first quarter 2014 financial results on Wednesday, May 14, 2014 . The press release will be followed by a conference call and webcast at 8:30 a.m. ET . Conference Call Information     Date: Wednesday,
View HTML
Toggle Summary Retrophin Initiates Global Access for RE-024 in Pantothenate Kinase-Associated Neurodegeneration (PKAN)
First Patient Scheduled to Be Dosed Outside the U.S. This Week NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced that it has made RE-024 available to physicians who are treating critically ill patients with pantothenate kinase-associated neurodegeneration (PKAN) worldwide
View HTML
Toggle Summary Retrophin Updates Financial Guidance for 2014 and 2015 and Provides Corporate Update
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced it is updating its revenue outlook for 2014 and 2015.                           Current revenue forecast       Previous revenue forecast 2014       $19 million - $21 million       $10 million - $12 million 2015       $35
View HTML
Toggle Summary Retrophin Reports Full-Year 2013 Financial Results
Management to Host Conference Call and Audio Webcast Today at 4:30 p.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today reported its financial results for the year ended December 31, 2013 . "2013 was a productive and eventful year for Retrophin," said Martin Shkreli , Founder
View HTML
Toggle Summary Retrophin Completes Acquisition of Manchester Pharmaceuticals
Transaction Transforms Retrophin into a Commercial Company with Two FDA-Approved Products Company Plans to Pursue Approval of Chenodal in CTX NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced the completion of the previously announced acquisition of Manchester
View HTML
Toggle Summary Retrophin Announces Agreement to Acquire Manchester Pharmaceuticals
Acquisition Brings Two FDA-Approved Products Management to Host Conference Call and Webcast Tomorrow at 8:30 a.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has signed an agreement to acquire Manchester Pharmaceuticals® LLC, a privately-held
View HTML
Toggle Summary Retrophin to Present at the 16th Annual BIO CEO & Investor Conference
Corporate update to be given February 11 at 9 a.m. EST NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced that Founder and CEO Martin Shkreli will present a corporate overview and update at the 16 th Annual BIO CEO & Investor Conference being held February 10-11 in New York
View HTML
Toggle Summary Retrophin Announces Pricing of Public Offering of Common Shares
Uplisted to NASDAQ Global Market Under Symbol "RTRX" NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX)(formerly OTCQB:RTRX) today announced the pricing of an underwritten public offering of 4,705,882 shares of its common stock, offered at a price of $8.50 per share.
View HTML